Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials
Articolo
Data di Pubblicazione:
2019
Abstract:
Background: We aim to understand whether all patients with hormonal receptor (HR)-positive (+)/human epidermal growth factor receptor-2 (HER2)-negative (-) metastatic breast cancer (MBC) should receive cyclin D-dependent kinase (CDK) 4/6 inhibitor-based therapy as a first-line approach.
Tipologia CRIS:
03A-Articolo su Rivista
Keywords:
Abemaciclib; Aromatase inhibitors; Fulvestrant; Metastatic breast cancer; Palbociclib; Ribociclib
Elenco autori:
Rossi V.; Berchialla P.; Giannarelli D.; Nistico C.; Ferretti G.; Gasparro S.; Russillo M.; Catania G.; Vigna L.; Mancusi R.L.; Bria E.; Montemurro F.; Cognetti F.; Fabi A.
Link alla scheda completa:
Link al Full Text:
Pubblicato in: